TY - JOUR
T1 - In Pursuit of Optimal Outcomes
T2 - A Framework for Quality Standards in Immune Effector Cell Therapy
AU - Committee on Quality Outcomes of the American Society of Transplant and Cellular Therapy
AU - Dandoy, Christopher E.
AU - Adams, Joan
AU - Artz, Andrew
AU - Bredeson, Christopher
AU - Dahi, Parastoo B.
AU - Dodd, Therese
AU - Jaglowski, Samantha
AU - Lehmann, Leslie
AU - LeMaistre, Charles F.
AU - Mian, Amir
AU - Neal, Alison
AU - Page, Kristen
AU - Rizzo, J. Douglas
AU - Rotz, Seth
AU - Sorror, Mohamed
AU - Steinberg, Amir
AU - Viswabandya, Auro
AU - Howard, Dianna S.
N1 - Publisher Copyright:
© 2024 The American Society for Transplantation and Cellular Therapy
PY - 2024/10
Y1 - 2024/10
N2 - Immune effector cell (IEC) therapy represents a transformative advancement in oncology, leveraging the immune system to combat various malignancies. This article outlines a comprehensive framework for establishing and maintaining quality standards in IEC therapy amidst rapid scientific and clinical advancements. We emphasize the integration of structured process measures, robust quality assurance, and meticulous outcome evaluation to ensure treatment efficacy and safety. Key components include multidisciplinary expertise, stringent accreditation protocols, and advanced data management systems, which facilitate standardized reporting and continual innovation. The collaborative effort among stakeholders—ranging from patients and healthcare providers to regulatory bodies—is crucial in delivering high-quality IEC therapies. This framework aims to enhance patient outcomes and cement the role of IEC therapy as a cornerstone of modern oncology, promoting continuous improvement and adherence to high standards across the therapeutic spectrum.
AB - Immune effector cell (IEC) therapy represents a transformative advancement in oncology, leveraging the immune system to combat various malignancies. This article outlines a comprehensive framework for establishing and maintaining quality standards in IEC therapy amidst rapid scientific and clinical advancements. We emphasize the integration of structured process measures, robust quality assurance, and meticulous outcome evaluation to ensure treatment efficacy and safety. Key components include multidisciplinary expertise, stringent accreditation protocols, and advanced data management systems, which facilitate standardized reporting and continual innovation. The collaborative effort among stakeholders—ranging from patients and healthcare providers to regulatory bodies—is crucial in delivering high-quality IEC therapies. This framework aims to enhance patient outcomes and cement the role of IEC therapy as a cornerstone of modern oncology, promoting continuous improvement and adherence to high standards across the therapeutic spectrum.
KW - Immune effector cell therapy
KW - Patient safety, quality of care
KW - Quality improvement
KW - Transplant and cellular therapy
UR - http://www.scopus.com/inward/record.url?scp=85200735546&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2024.07.011
DO - 10.1016/j.jtct.2024.07.011
M3 - Editorial
AN - SCOPUS:85200735546
SN - 2666-6375
VL - 30
SP - 942
EP - 954
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 10
ER -